Stockscreener 앱 받기
2.40
0.41%
-0.01
시간 외 거래:
2.39
-0.010
-0.42%
Organogenesis Holdings Inc 주식(ORGO)의 최신 뉴스
Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked - Seeking Alpha
ORGO Q1 2026 Earnings: Significant EPS Miss Highlights Persistent ChallengesEPS Guidance Update - newsline.com
ORGO Q1 2026 Earnings: EPS Misses Estimates by 29.66% as Losses WidenNegative Surprise Momentum - newsline.com
The Body as Blueprint - lifehealth.com
Organogenesis plans rolling BLA submission for ReNu by year-end - Investing.com
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts - PR Newswire
Number of shareholders of Organogenesis Holdings, Inc. Class A – DUS:2PQ - TradingView
Organogenesis shares jump 20% following positive clinical trial results - MSN
Organogenesis Holdings Faces Selling Pressure as ORGO Slips to $2.57Oversold Bounce Ideas - newsline.com
Organogenesis Holdings (ORGO) Declines 1.5% as Stock Tests Key Support ZoneFund Manager Survey - The Legal Advocate
Truist initiates Organogenesis stock at Hold on reimbursement shifts - Investing.com UK
Truist initiates Organogenesis stock at Hold on reimbursement shifts By Investing.com - Investing.com India
Truist Initiates Organogenesis Holdings at Hold With $3 Price Target - marketscreener.com
ORGO stock rallies after hours on clearing regulatory pathway for pain relief treatment - MSN
- The Legal Advocate
Organogenesis Holdings (ORGO) Edges Lower as Stock Hovers Near Key SupportBullish Percent Index - The Legal Advocate
Organogenesis rises as PuraPlyAM succeeds in diabetic foot ulcers - MSN
Organogenesis Holdings (ORGO) Holds Steady at $2.66 – Consolidation Phase in PlayALMA Signal - The Legal Advocate
ORGO Q1 2026 Earnings: EPS Falls Short of Estimates Amid Operational ChallengesEPS Miss Report - newsline.com
ORGO Q1 2026 Earnings: Significant EPS Miss Raises ConcernsEarnings Cycle Outlook - newsline.com
Organogenesis Holdings stock (US68620V1026): BTIG rating cut puts focus on outlook after Q1 update - AD HOC NEWS
Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update - Insider Monkey
Organogenesis outlines 2025 revenue guidance of $500M–$525M as CMS policy shift drives growth outlook - MSN
Organogenesis Holdings (ORGO) Q1 2026 Earnings Miss by Significant: Key TakeawaysQuarterly Profit Report - newsline.com
Organogenesis Holdings stock (US68620V1026): FDA warning letter and Nasdaq notice put focus on compl - AD HOC NEWS
Organogenesis Holdings stock (US68620V1026): shares react to earnings and outlook update - AD HOC NEWS
Organogenesis Holdings Inc.Class A (NQ: ORGO - FinancialContent
Organogenesis Holdings stock (US68620V1026): Q1 earnings miss on revenue and EPS - AD HOC NEWS
TradingKey - TradingKey
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q1 2026 Earnings Call Transcript - Insider Monkey
RI skin-maker Organogenesis reports steep Q1 loss amid CMS policy change - The Business Journals
Organogenesis (ORGO) Q1 2026 Earnings Transcript - AOL.com
BTIG downgrades Organogenesis stock rating to neutral on reimbursement headwinds By Investing.com - Investing.com South Africa
BTIG Downgrades Organogenesis(ORGO.US) to Hold Rating - Moomoo
Organogenesis forecasts $270M-$310M 2026 revenue amid prolonged CMS-related recovery - MSN
symbol__ Stock Quote Price and Forecast - CNN
Organogenesis Holdings Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Organogenesis Q1 Earnings Call Highlights - Barchart.com
BTIG downgrades Organogenesis stock rating to neutral on reimbursement headwinds - Investing.com UK
Organogenesis Holdings Inc. (ORGO) Stock Report: Exploring A Potential 216% Upside - DirectorsTalk Interviews
Skin Substitute Market Is Going to Boom Rapidly |Organogenesis - openPR.com
Earnings call transcript: Organogenesis Q1 2026 earnings miss and stock reacts By Investing.com - Investing.com South Africa
Earnings call transcript: Organogenesis Q1 2026 earnings miss and stock reacts - Investing.com Australia
2.11%
자본화:
|
볼륨(24시간):